Clinical trials: Aripiprazole
Device Latency
Substudy 'B' of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1)
The purpose of this study is to determine the accuracy of IEM detection by the MIND1 System by completing a series of Patch applications and IEM ingestions in the clinic.
- Trial name
- OSMITTER (NCT02404532)
- Testing
- MIND1 System
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Device Latency
Substudy of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1)
The purpose of this study was to determine the accuracy of IEM detection by the MIND1 System by completing a series of Patch applications and IEM ingestions in the clinic.
- Trial name
- OSMITTER (NCT02091882)
- Testing
- Combination product of Aripiprazole + IEM + Sensor + MIND1 Application
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depression
Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism
Reduction of volume of the hippocampus has been associated with major depression in many studies. It has been suggested that antidepressants may protect against hippocampus volume loss in humans associated with multiple episodes…
- Trial name
- NCT00704860
- Testing
- Open label pharmacotherapy
- Where
- Canada
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- University of Ottawa
Schizophrenia
Pan European Collaboration on Antipsychotic Naive Schizophrenia (PECANS)
The investigators want to relate disturbances in first-episode schizophrenic patients in (dopaminergic) D2 receptors, brain structure, brain function, and information processing to each other and to psychopathology.
- Trial name
- PECANS (NCT01154829)
- Testing
- amisulpride, aripiprazole
- Where
- Denmark
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Schizophrenia
Standard Comprehensive Intervention to Treat First-episode Schizophrenia
Schizophrenia is not a curable but a treatable disease by antipsychotics. Kinds of atypical antipsychotics are widely used since 1990s' in China.
- Trial name
- NCT01057849
- Testing
- risperidone, olanzapine, Aripiprazole
- Where
- 6 sites in China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Peking University
Schizophrenia
Safety and Efficacy of Aripiprazole and Ziprasidone Among Schizophrenic Patients With Metabolic Syndrome
Introduction: Schizophrenia is a serious mental illness. For majority of patients it is a lifetime condition,characterized by intermittent episodes of hospitalization due to relapse or acute symptom exacerbation.
- Trial name
- NCT01714011
- Testing
- Ziprasidone, Aripiprazole
- Where
- Malaysia
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- University of Malaya
Schizophrenia, Bipolar
Heart Rate Changes in Schizophrenic and Bipolar Patients Under the Medication of Aripiprazole and Quetiapine
The goal of this research is investigating the heart rate changes in schizophrenic and bipolar patients under the medication of aripiprazole and quetiapine.
- Trial name
- HeartAriQue (NCT01047215)
- Testing
- Aripiprazole; Quetiapine
- Where
- Taiwan
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Taichung Veterans General Hospital
Pharmacokinetics, Cytochrome P-450 CYP2D6
Open Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Aripiprazole When Coadministered To Healthy Subjects
The goal of this study is to evaluate the effect of multiple doses of Desvenlafaxine Sustained Release (SR) on the pharmacokinetics of Aripiprazole when coadministered to healthy adult subjects.
- Conditions
- Pharmacokinetics, Cytochrome P-450 CYP2D6, CYP3A4 Protein, Human
- Trial name
- NCT01188668
- Testing
- Aripiprazole, Aripiprazole + desvenlafaxine succinate sustained release
- Where
- 2 sites in United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Pfizer
Psychiatry
Comparison of Bone Mineral Density Changes During Tx With Risperidone or Aripiprazole in Adolescents
This study examines if the use of antipsychotic medications might contribute to an interruption in bone mineral development and/or a reduction in bone mineral content in adolescents.
- Trial name
- NCT00573716
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Creighton University
Diagnosis and Treatment of Depression
A Study of Diagnosis and Treatment of Depression Based on Biological Evidence of Dopamine Reward Pathway
This study will recruit depressed patients unresponsive to selective serotonin reuptake inhibitor antidepressant treatment, first-degree relatives (parents or siblings) of depressed patients, schizophrenia, Parkinson's disease…
- Trial name
- NCT03148509
- Testing
- risperidone, aripiprazole, bupropion
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Peking University
Psychosis, Negative Symptoms With Primary Psychotic Disorder
Add-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First Psychosis
Antipsychotics affects the brain's dopamine system, and the drugs reduce delusions, hallucinations, and disorganized thinking, which are cardinal symptoms of psychotic disorders. However, negative symptoms e.g.
- Trial name
- AMEND (NCT04789915)
- Testing
- Memantine
- Where
- Denmark
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Bjorn H. Ebdrup
First-Episode Psychosis, Bipolar Disorder
Comparison of Aripiprazole Versus Risperidone on Brain Morphology Using MRI
Significant changes in brain morphology are observed in people with first-episode psychosis. Studies have shown that total brain volume and particular brain structures are decreased in people with psychosis disorders.
- Trial name
- CARB (NCT02334904)
- Testing
- Aripiprazole, Risperidone
- Where
- Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Depressive Disorder
A PET Study in Healthy Volunteers
This will be an open label, non-randomised [11C]PHNO PET study using healthy male volunteers. Each volunteer will undergo 4 [11C]PHNO PET scans to allow for further characterisation of this radioligand and examine the effects of…
- Trial name
- NCT01424449
- Testing
- [11C]PHNO, Aripiprazole
- Where
- United Kingdom
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Alzheimer's Disease
Drug Interaction Study Between AZD3480 and Aripiprazole in Healthy Subjects
The purpose of the study is to evaluate if AZD3480 and warfarin interact with each other or not, i.e. show the same or altered plasma concentration profiles when co-administered compared to administered alone.
- Trial name
- NCT00689559
- Testing
- AZD3480, Aripiprazole
- Where
- Sweden
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Schizophrenia, Type 2 Diabetes Mellitus
Changes in Adiposity, Metabolic Measures From Atypicals to Aripiprazole
This proposal aims to use well-validated methodologies such as dual energy x-ray absorptiometry (DEXA), frequently sampled oral glucose tolerance tests (fsOGTTs), and hyperinsulinemic euglycemic clamps to characterize the…
- Trial name
- BMS (NCT00205660)
- Testing
- Stayers, Switchers
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Bioequivalence
Bioequivalence Study of Bosiqing and ABILIFY Under Fasting/Fed Condition
To compare the rate and extent of absorption of Aripiprazole Orally disintegrating tablets 10 mg of Chengdu Kanghong Pharmaceutical Group Co.,Ltd, China and ABILIFY (Aripiprazole) 10 mg orodispersible tablets of Otsuka…
- Trial name
- NCT03232710
- Testing
- Bosiqing, abilify
- Where
- China
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Chengdu Kanghong Pharmaceutical Group Co., Ltd.
Schizophrenia Disorder, Schizophreniform Disorder
MicroRNAs as Biomarkers in First Episode Schizophrenia
This study investigates whether tiny molecules called microRNAs (miRNAs), found in special brain-derived "packages" (neural-derived extracellular vesicles, or NDEs) that travel from the brain into the blood, can serve as helpful…
- Conditions
- Schizophrenia Disorder, Schizophreniform Disorder, Schizoaffective Disorder, Psychosis Not Otherwise Specified (NOS)
- Trial name
- MIRFEST (NCT07703670)
- Testing
- Plasma NDE miRNA Sequencing, Whole Genome Sequencing
- Where
- United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Healthy Male Adults
Bioequivalence Between Single Administration of ASC-01 (Aripiprazole/Sertraline Combination Drug) and Concomitant Single Administration of Aripiprazole and Sertraline, and Food Effect on Pharmacokinetics of ASC-01 in Healthy Male Adults
To investigate the bioequivalence of aripiprazole between administration of one ASC-01 tablet (aripiprazole 3 mg/sertraline 100 mg combination drug) and concomitant administration of one aripiprazole 3-mg tablet and two…
- Trial name
- NCT03342963
- Testing
- ASC-01, Aripiprazole and sertraline
- Where
- Japan
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Diabetes
Examining the Effects of Antipsychotic Medications on Insulin Sensitivity
This study will examine the effects of two different antipsychotic medications on control of blood sugar in people who are at risk of diabetes but mentally healthy.
- Trial name
- NCT00895921
- Testing
- Olanzapine, Aripiprazole
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Veterans Medical Research Foundation
Major Depressive Disorder (MDD), Rumination
Neurobiological Mechanisms of Pathological Rumination and Effects of Aripiprazole
This randomized, single-blind (assessor-blind) controlled trial aims to investigate the efficacy of aripiprazole as an augmentation strategy for treating pathological rumination in patients with major depressive disorder (MDD).
- Trial name
- NCT06937476
- Testing
- Escitalopram, Aripiprazole 5mg
- Where
- China
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Central South University